Clinical trials: Complicated Intra-abdominal Infections (cIAI)
Urinary Tract Infection (cUTI), Intra-abdominal Infection (cIAI) and
Reporting Patterns and Results of Initial Antibiotic Treatment in Patients With cUTI, cIAI,NP Including VAP
Reporting patterns and results of initial antibiotic treatment in patients with complicated urinary tract infection (cUTI), complicated intra-abdominal infection (cIAI) and nosocomial pneumonia (NP) including…
- Conditions
- Urinary Tract Infection (cUTI), Intra-abdominal Infection (cIAI) and, Nosocomial Pneumonia (NP)
- Trial name
- RECOMMEND (NCT02364284)
- Where
- 27 sites in Brazil, France and 4 more
- Volunteers
- 1,322 people
- Sponsor
- Pfizer
Intra-Abdominal Infections, Skin Disease, Infectious
Post-Authorization Study Evaluating Safety Of Tigecycline
This is a study to evaluate the safety of tigecycline in patients with complicated intra-abdominal infections (cIAI) and complicated skin and soft tissue infections (cSSTI) under real practice in the usual hospital setting and…
- Conditions
- Intra-Abdominal Infections, Skin Disease, Infectious, Soft Tissues Infections
- Trial name
- HORUS (NCT00827541)
- Testing
- Tigecycline
- Volunteers
- 115 people
- Sponsor
- Pfizer
Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection
Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)
The study will evaluate the efficacy and safety of imipenem+cilastatin/relebactam (IMI/REL, MK-7655A) in Japanese participants with complicated intra-abdominal infection (cIAI) or complicated urinary tract infection (cUTI).
- Trial name
- NCT03293485
- Testing
- Imipenem+Cilastatin/Relebactam
- Where
- 29 sites in Japan
- Volunteers
- 83 people
- Sponsor
- Merck Sharp & Dohme LLC
Intra-abdominal Infections
LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI)
The purpose of the study was to evaluate whether LYS228 can be developed for the treatment of complicated intra-abdominal infections.
- Trial name
- NCT03354754
- Testing
- LYS228, Standard of care therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Intra-abdominal Infections
Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)
The purpose of this study is to evaluate the efficacy, safety and tolerability of adding 125 mg or 250 mg doses of relebactam (MK-7655) to imipenem/cilastatin in adults 18 years or older with Complicated Intra-Abdominal Infection…
- Trial name
- NCT01506271
- Testing
- Relebactam 250 mg, Relebactam 125 mg, Imipenem/cilastatin
- Volunteers
- 351 people
- Sponsor
- Merck Sharp & Dohme LLC
Intra Abdominal Infections
Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)
This is a prospective, Phase 3, randomized, multi-center, double-blind study of the efficacy, tolerability and safety of sulopenem followed by sulopenem-etzadroxil/probenecid versus ertapenem followed by…
- Trial name
- NCT03358576
- Testing
- Ertapenem, Sulopenem-Etzadroxil/Probenecid, Ciprofloxacin
- Where
- 42 sites in United States, Bulgaria and 5 more
- Volunteers
- 674 people
- Sponsor
- Iterum Therapeutics, International Limited
Complicated Intra-Abdominal Infection
Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
The purpose of this study is to evaluate the effects of Ceftazidime Avibactam plus Metronidazole compared to Meropenem for treating hospitalized patients with complicated intra-abdominal infections.
- Trial name
- NCT01499290
- Testing
- CAZ-AVI, Metronidazole, Meropenem
- Where
- 56 sites in United States, Argentina and 18 more
- Volunteers
- 493 people
- Sponsor
- Pfizer
Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP)
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections
The study will evaluate the efficacy and safety of Meropenem and Pralurbactam versus Best Available Therapy in the treatment of Carbapenem-Resistant Enterobacteriaceae Infections.
- Conditions
- Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP), Complicated Intra-abdominal Infection (cIAI), Complicated Urinary Tract Infection (cUTI)
- Trial name
- NCT07089186
- Testing
- Meropenem and Pralurbactam, Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Gram-Negative Bacterial Infections
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants
The primary purpose of this study is to understand the pharmacokinetics (PK) of single and multiple doses of cefiderocol in children from birth to less than 3 months of age with suspected or confirmed aerobic Gram-negative…
- Trial name
- NCT06086626
- Testing
- Cefiderocol, Standard of Care
- Where
- 4 sites in United States, South Africa and 1 more
- Volunteers
- 30 people
- Sponsor
- Shionogi
Gram-negative Bacterial Infections, Bloodstream Infections (BSI)
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants
The primary objectives of this study are: To assess the safety and tolerability of cefiderocol after single-dose administration in hospitalized paediatric participants 3 months to < 18 years of age with suspected or confirmed…
- Conditions
- Gram-negative Bacterial Infections, Bloodstream Infections (BSI), Complicated Intra-abdominal Infection (cIAI), Hospital Acquired Pneumonia (HAP)
- Trial name
- NCT04335539
- Testing
- Cefiderocol, Standard of Care
- Where
- 23 sites in Belgium, Estonia and 7 more
- Volunteers
- 53 people
- Sponsor
- Shionogi
Abdominal Abscess
Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cIAI
In light of tigecycline's activity against these resistant bacteria, tigecycline may represent a viable new therapy for complicated intra-abdominal infections.
- Trial name
- NCT00488306
- Testing
- tigecycline
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Intra-abdominal Infections
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI
This is a Phase 3, randomized, double-blind, multicenter, positive control study to assess the efficacy, safety, and pharmacokinetics of Meropenem and Pralurbactam compared with Ceftazidime-avibactam in combination with…
- Trial name
- NCT06633718
- Testing
- Meropenem and Pralurbactam, Saline, Ceftazidime-avibactam
- Where
- China
- Volunteers
- 786 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Appendicitis, Cholecystitis
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)
This is a study of the safety and efficacy of tigecycline to ceftriaxone sodium plus metronidazole in hospitalized subjects with cIAI. Subjects will be followed for efficacy through the test-of-cure assessment.
- Conditions
- Appendicitis, Cholecystitis, Diverticulitis, Intra-Abdominal Abscess
- Trial name
- NCT00230971
- Testing
- tigecycline, ceftriaxone plus metronidazole
- Where
- 68 sites in Australia, China and 17 more
- Volunteers
- 473 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Secondary Peritonitis, Abscess, Intra-Abdominal
Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)
This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from a cIAI and take at least one dose of Moxifloxacin infusion.The primary objective is…
- Trial name
- NCT01096511
- Testing
- Moxifloxacin (Avelox, BAY12-8039)
- Where
- China
- Volunteers
- 1,001 people
- Sponsor
- Bayer
Complicated Intra-Abdominal Infection
MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)
This study aims to evaluate the safety and tolerability of MK-7625A (ceftolozane/tazobactam) plus metronidazole, compared with that of meropenem in pediatric participants with cIAI.
- Trial name
- NCT03217136
- Testing
- Ceftolozane/Tazobactam, Metronidazole, Meropenem
- Where
- 50 sites in United States, Brazil and 10 more
- Volunteers
- 94 people
- Sponsor
- Merck Sharp & Dohme LLC
Complicated Intra-abdominal Infections (cIAI)
A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)
A Phase 2 trial to assess safety, tolerability, and pharmacokinetics of eravacycline in pediatric patients aged 8 to <18 years with cIAI.
- Trial name
- NCT06794541
- Testing
- IV Eravacycline 2mg/kg, IV Eravacycline 1.5mg/kg
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Tetraphase Pharmaceuticals, Inc
Complicated Intra-abdominal Infection (cIAI), Systemic Inflammatory Response
Ulinastatin on Systemic Immune-Inflammation in Patients With Complicated Intra-Abdominal Infection
Complicated intra-abdominal infection (cIAI) triggers dysregulated systemic inflammation and immune paralysis leading to high organ failure and death risk.
- Conditions
- Complicated Intra-abdominal Infection (cIAI), Systemic Inflammatory Response, Sepsis, Immune Dysfunction
- Trial name
- UTI-cIAI (NCT07672496)
- Testing
- ulinastatin, Normal Saline (0.9% NaCl)
- Where
- China
- Volunteers
- 165 people
- Sponsor
- Fujian Medical University Union Hospital
Complicated Intra-abdominal Infection
Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections
This is a Phase 3, multicenter, prospective, randomized, double-blind, double dummy study of CXA-201 Intravenous (IV) infusions (1500mg q8h) and metronidazole (500mg q8h) versus meropenem (1000mg q8h)for the treatment of adults…
- Trial name
- NCT01445678
- Testing
- CXA-201 and metronidazole, Meropenem
- Where
- 61 sites in United States, Argentina and 13 more
- Volunteers
- 494 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)